Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Manitoba

$27,000.00

Tuning CAR-T cells to preferentially respond to high antigen densities to enable precise tumour targeting

FY 2025-26

Summary
Chimeric antigen receptor (CAR) T cell therapy is a cancer treatment that has been very successful in treating some types of blood cancers. This therapy uses a patient’s immune system to fight cancer. This is done by taking T cells, key cells from the immune system, from a patient and adding a molecule to it called CAR. The CAR will make the cells search for a specific target on the cancer cells and attack them. One of the key limitations of CAR-T cell therapy is identifying suitable targets on cancer cells to attack, as these are often also present on healthy cells, but at lower levels. This causes the T cells with the CAR (CAR-T cells) to attack these healthy cells. The aim of this project is to make a method that allows CAR-T cell therapies to attack only the cancer cells with a larger number of target molecules on them so that the healthy cells are spared. To do this, parts of the CAR that cause the T cells to activate and attack cells with their target will be reduced. This should make it harder for CAR-T cells to activate, ensuring that they only activate and attack when there are a lot of their targets on the cells as in the case of cancer cells.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572911
Name
O'Keefe Kailyn D
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Tuning CAR-T cells to preferentially respond to high antigen densities to enable precise tumour targeting
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antigen Sensitivity; Bioengineering; Biotechnology; Cancer Therapy; Car-T Cells; Crispr; Immunotherapy; Molecular Biology; Signalling; T Cell Biology
Abstract
Chimeric antigen receptor (CAR) T cell therapy is a cancer treatment that has been very successful in treating some types of blood cancers. This therapy uses a patient’s immune system to fight cancer. This is done by taking T cells, key cells from the immune system, from a patient and adding a molecule to it called CAR. The CAR will make the cells search for a specific target on the cancer cells and attack them. One of the key limitations of CAR-T cell therapy is identifying suitable targets on cancer cells to attack, as these are often also present on healthy cells, but at lower levels. This causes the T cells with the CAR (CAR-T cells) to attack these healthy cells. The aim of this project is to make a method that allows CAR-T cell therapies to attack only the cancer cells with a larger number of target molecules on them so that the healthy cells are spared. To do this, parts of the CAR that cause the T cells to activate and attack cells with their target will be reduced. This should make it harder for CAR-T cells to activate, ensuring that they only activate and attack when there are a lot of their targets on the cells as in the case of cancer cells.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
O'Keefe, Kailyn D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~